IL33 and neoplasm: Treatment with chemotherapeutics and ICIs adversely promotes IL33+ tumor growth and metastasis through the release of IL33, which systemically expands immunoregulatory ST2+ cells in mouse tumor models, as with the unexpected hyperprogression that is sometimes seen in ICI-treated patients [14,15].